This abstract, #3017 is not yet (or will not be) available on the ASCO website.
Bowel perforation and fistula formation in colorectal cancer patients treated on Eastern Cooperative Oncology Group (ECOG) studies E2200 and E3200
B.J> Giantonio, H.X. Chen, P.J. Catalano, N.J. Meropol, P.J. O'Dwyer, A.I.B. Benson;
Abramson Cancer Center, Univ of Pennsylvania, Philadelphia, PA; The National Cancer Institute, Rockville, MD; Dana-Farber Cancer Institute, Boston, MA; Fox Chase Cancer Center, Philadelphia, Pa; Northwestern Univ, Chicago, IL
The background information stated that "the addition of bevacizumab (rh-anti-VEGF) to frontline chemotherapy for advanced colorectal cancer (CRC) improves survival. Bowel perforation and fistula formation have been reported in colorectal cancer patients treated with bevacizumab."
Conclusions: "Use of bevacizumab in colorectal cancer patients may be associated with an increased risk of bowel perforation and fistula formation. Although an uncommon occurrence, bowel perforation should be considered in colorectal cancer patients treated with bevacizumab who develop symptoms consistent with this diagnosis."
|Remember we are NOT Doctors and have NO medical training.|
This site is like an Encyclopedia - there are many pages, many links on many topics.
Support our work with any size DONATION - see left side of any page - for how to donate. You can help raise awareness of CAM.